DUBLIN--(BUSINESS WIRE)--The "Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis" report has been added to ResearchAndMarkets.com's offering.
According to the report, T-cell Immunotherapy is a rapidly expanding field of oncology. This therapy is intended to overcome the challenge of getting the right type of T-cell to the target tumor. It makes use of patients' own immune cells to fight cancer. These immune cells are obtained from the patient and genetically engineered before their use for the treatment.
Numerous researches are being performed across the globe to explore the potential of T-cell Immunotherapy for the treatment of different types of cancer. During these researches, T-cell Immunotherapies have demonstrated clinical successes on some accounts along with some critical issues on others. Overall, this therapy has emerged as one of the innovative and potent arm of the immunotherapeutic market.
The report provides an in-depth study on the current state of the T-Cell Immunotherapy industry. Recently, the USFDA approved two T-cell Immunotherapies for the treatment of cancer. The approved therapies belong to the class of CAR T-cell Immunotherapies.
CAR T-cell therapies are the most researched type of therapy as they have shown exceptional results during clinical trials. The market for such T-cell Immunotherapies is forecasted to grow at an exponential rate owing to the high venture capitalist investments and increasing research related activities in this field.
Furthermore, the global and regional prevalence of major types of cancer for which T-cell Immunotherapy is used is highlighted in the report. These cancers include leukemia, lymphoma, melanoma, ovarian cancer, and bladder cancer amongst others. This will help the companies to gain knowledge regarding the target population for various immunotherapies globally, and at regional level.
Moreover, an extensive analysis of the pipeline of T-cell Immunotherapies has been provided in the report. This analysis has been performed on the basis of phases, therapeutic indications, geographies, vectors used, technology types, and key players. This segment also covers the list of the key ongoing clinical trials along with their clinical phases by industry and research collaborations.
The last section of the report discusses about the key players, such as Novartis, Gilead Sciences and Juno Therapeutics among others, in the global T-cell Immunotherapy industry.
Key Topics Covered
1. Analyst View
2. Research Methodology
3. Introduction
4. Global T-Cell Immunotherapy Market for Cancer
5. Global CAR T-Cell Immunotherapy Market for Cancer
6. Commercialized CAR T-Cell Immunotherapies for Cancer
7. Major Therapeutic Areas for T-Cell Immunotherapies
8. T-Cell Immunotherapy Pipeline Analysis
9. Market Opportunities
10. Key Player Analysis
- Adaptimmune Therapeutics PLC
- Atara Biotherapeutics, Inc.
- Celgene Corporation
- Cell Medica
- Cellular Biomedicine Group
- Gilead Sciences, Inc.
- GlaxoSmithKline
- Gradalis, Inc.
- Immunocore Ltd.
- Immunovative Therapies, Ltd.
- Inovio Pharmaceuticals, Inc.
- Iovance Biotherapeutics, Inc. (Formerly Lion Biotechnologies, Inc.)
- Juno Therapeutics, Inc.
- Novartis International AG
- Tessa Therapeutics Pte Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/f99hgx/global_cancer_and?w=4
